Clinical trial
PhII 5-Azacytidine Plus Valproic Acid and Eventually Atra in Intermediate II and…
NCT00439673 · Gruppo Italiano Malattie EMatologiche dell'Adulto, Other · Completed
Key facts
| NCT number | NCT00439673 |
|---|---|
| Title | PhII 5-Azacytidine Plus Valproic Acid and Eventually Atra in Intermediate II and High Risk MDS |
| Official title | A Open Label, Phase II, Non Randomized, Clinical Trial of Chemotherapy Treatment With 5-Azacytidine Plus Valproic Acid and Eventually Atra for Patients Diagnosed With Intermediate II and High Risk Myelodysplastic Syndrome (MDS). EudraCT Number 2005-004811-31. GIMEMA Protocol MDS0205 |
| Lead sponsor | Gruppo Italiano Malattie EMatologiche dell'Adulto, Other |
| Status | Completed |
| Phase | Phase 2 |
| Study type | Interventional |
| Conditions | Myelodysplastic Syndromes |
| Intervention type | Drug |
| Interventions | 5-Azacytidine, Valproic Acid, ATRA |
| Enrollment | 62 |
| Start date | May 1, 2007 |
| Primary completion | Jul 1, 2010 |
| Completion | Jul 1, 2010 |
| First posted | Feb 26, 2007 |
| Last update posted | Aug 7, 2018 |
| Countries | Italy |
At a glance
- 1–9 Study sites
- Yes Results posted
- None Linked FDA submissions
Counts are shown as ranges. Exact figures, trends and every underlying record are available in Orca1.
About ClinicalTrials.gov studies
ClinicalTrials.gov is the U.S. National Library of Medicine's registry of clinical studies conducted around the world. Contact and investigator details are not shown here.
Source: U.S. National Library of Medicine (NLM), ClinicalTrials.gov · Source date: